Tesamorelin

FDA Approved

Tesamorelin

Category
Growth Hormone
Aliases
Egrifta, Egrifta SV
Administration
Subcutaneous injection (once daily)

Documented side effects

Tier 1 · Peer-reviewed / regulatory

Injection site reactions

Mild redness, swelling, or discomfort at the site of injection.

Joint pain

Some users report discomfort in the joints during use.

Peripheral edema

Mild swelling, typically in the lower legs or feet, has been reported with use.

Potential blood sugar elevation

May raise blood glucose levels as a downstream effect of increased growth hormone activity.